• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.在严重肢体缺血治疗试验中使用替代方法评估复合终点。
Am Heart J. 2012 Sep;164(3):277-84. doi: 10.1016/j.ahj.2012.07.002.
2
Standardizing end points in perioperative trials: towards a core and extended outcome set.规范围手术期试验的终点：迈向核心结局集和扩展结局集
Br J Anaesth. 2016 May;116(5):586-9. doi: 10.1093/bja/aew066.
3
Composite End Points in Clinical Research: A Time for Reappraisal.临床研究中的复合终点：重新评估的时刻。
Circulation. 2017 Jun 6;135(23):2299-2307. doi: 10.1161/CIRCULATIONAHA.117.026229.
4
You get what you measure: evaluating endpoints in MS clinical trials.你衡量什么，就会得到什么：评估多发性硬化症临床试验中的终点指标。
Neurology. 2008 Aug 26;71(9):620-1. doi: 10.1212/01.wnl.0000324619.41610.b8. Epub 2008 Aug 6.
5
Value of central event adjudication.中心事件裁定的价值。
Stroke. 2009 Nov;40(11):e638; author reply e639-40. doi: 10.1161/STROKEAHA.109.562181. Epub 2009 Sep 17.
6
Time to change the primary outcome of lupus trials.是时候改变狼疮试验的主要结局了。
Ann Rheum Dis. 2019 May;78(5):581-582. doi: 10.1136/annrheumdis-2018-213788. Epub 2018 Jun 19.
7
An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease.一种评估AN1792阿尔茨海默病疫苗疗效的替代方法。
Neurology. 2008 Aug 26;71(9):697; author reply 697-8. doi: 10.1212/01.wnl.0000325484.81127.15.
8
Interim analyses in clinical trials: why do we plan them?临床试验中的期中分析：我们为何要进行规划？
J Clin Oncol. 2000 Dec 15;18(24):4007-8. doi: 10.1200/JCO.2000.18.24.4007.
9
Equivalence approaches.等效性方法。
Clin Pharmacol Ther. 2002 Sep;72(3):229-37. doi: 10.1067/mcp.2002.126705.
10
End points in advanced colon cancer clinical trials: a review and proposal.晚期结肠癌临床试验的终点：综述与建议
J Clin Oncol. 2007 Aug 20;25(24):3572-5. doi: 10.1200/JCO.2007.12.1368.

引用本文的文献

1
Postoperative Pulmonary Complications' Association with Sugammadex versus Neostigmine: A Retrospective Registry Analysis.术后肺部并发症与舒更葡糖钠对比新斯的明的相关性：一项回顾性注册研究分析
Anesthesiology. 2021 Jun 1;134(6):862-873. doi: 10.1097/ALN.0000000000003735.
2
Overcoming underpowering: Trial simulations and a global rank end point to optimize clinical trials in children with heart disease.克服无效性：试验模拟和全球排名终点优化心脏病儿童临床试验。
Am Heart J. 2020 Aug;226:188-197. doi: 10.1016/j.ahj.2020.05.011. Epub 2020 May 20.
3
Win Ratio -An Intuitive and Easy-To-Interpret Composite Outcome in Medical Studies.胜率——医学研究中一种直观且易于解读的综合结果
Shanghai Arch Psychiatry. 2017 Feb 25;29(1):55-60. doi: 10.11919/j.issn.1002-0829.217011.
4
An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.最优 Wilcoxon-Mann-Whitney 检验用于比较死亡率和连续结果。
Stat Methods Med Res. 2018 Aug;27(8):2384-2400. doi: 10.1177/0962280216680524. Epub 2016 Dec 29.
5
Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.存在死亡删失观测值时Wilcoxon-Mann-Whitney检验的功效及样本量计算
Stat Med. 2015 Feb 10;34(3):406-31. doi: 10.1002/sim.6355. Epub 2014 Nov 13.
6
Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial.对难治性严重肢体缺血门诊患者双侧给予自体CD133+细胞：来自一项试点随机、双盲、安慰剂对照试验的经验教训。
Cytotherapy. 2014 Dec;16(12):1720-32. doi: 10.1016/j.jcyt.2014.07.011. Epub 2014 Sep 18.
7
Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database.外周血管疾病的临床试验：研究进展与试验设计：对ClinicalTrials.gov数据库的评估
Circulation. 2014 Nov 11;130(20):1812-9. doi: 10.1161/CIRCULATIONAHA.114.011021. Epub 2014 Sep 19.
8
Lower extremity amputation in peripheral artery disease: improving patient outcomes.外周动脉疾病中的下肢截肢：改善患者预后。
Vasc Health Risk Manag. 2014 Jul 16;10:417-24. doi: 10.2147/VHRM.S50588. eCollection 2014.

本文引用的文献

1
Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.与传统复合终点相比，加权复合终点对随机对照试验设计的影响。
Stat Methods Med Res. 2015 Dec;24(6):980-8. doi: 10.1177/0962280211436004. Epub 2012 Jan 24.
2
Size and power estimation for the Wilcoxon-Mann-Whitney test for ordered categorical data.有序分类数据的 Wilcoxon-Mann-Whitney 检验的大小和功效估计。
Stat Med. 2011 Dec 20;30(29):3461-70. doi: 10.1002/sim.4407. Epub 2011 Nov 15.
3
The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities.胜率：一种基于临床重点的临床试验中综合终点分析的新方法。
Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6.
4
Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia.成纤维细胞生长因子 NV1FGF 对截肢和死亡的影响：基因治疗严重肢体缺血的随机安慰剂对照试验。
Lancet. 2011 Jun 4;377(9781):1929-37. doi: 10.1016/S0140-6736(11)60394-2. Epub 2011 May 28.
5
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial.细化临床试验综合结局：ASSENT-3 试验中评估一种新型溶栓药物的安全性和有效性的应用。
Am Heart J. 2011 May;161(5):848-54. doi: 10.1016/j.ahj.2010.12.026. Epub 2011 Apr 7.
6
Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA).经导管动脉内骨髓单个核细胞输注治疗严重肢体缺血患者的随机起始、安慰剂对照的试验研究（PROVASA）。
Circ Cardiovasc Interv. 2011 Feb 1;4(1):26-37. doi: 10.1161/CIRCINTERVENTIONS.110.958348. Epub 2011 Jan 4.
7
Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.患者特异性肌肉内注射 HGF 质粒基因治疗对缺血性下肢溃疡患者肢体灌注和创面愈合的安全性和疗效：HGF-0205 试验结果。
J Vasc Surg. 2010 Dec;52(6):1525-30. doi: 10.1016/j.jvs.2010.07.044.
8
A global rank end point for clinical trials in acute heart failure.急性心力衰竭临床试验的全球排名终点。
Circ Heart Fail. 2010 Sep;3(5):643-6. doi: 10.1161/CIRCHEARTFAILURE.109.926030.
9
Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review.定义、报告和解释临床试验中的综合结局：系统综述。
BMJ. 2010 Aug 18;341:c3920. doi: 10.1136/bmj.c3920.
10
Stenting versus endarterectomy for treatment of carotid-artery stenosis.颈动脉狭窄的血管内支架成形术与颈动脉内膜切除术治疗的比较。
N Engl J Med. 2010 Jul 1;363(1):11-23. doi: 10.1056/NEJMoa0912321. Epub 2010 May 26.

Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.

作者信息

Subherwal Sumeet, Anstrom Kevin J, Jones William S, Felker Michael G, Misra Sanjay, Conte Michael S, Hiatt William R, Patel Manesh R

出版信息

Am Heart J. 2012 Sep;164(3):277-84. doi: 10.1016/j.ahj.2012.07.002.

DOI:10.1016/j.ahj.2012.07.002
PMID:22980292
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3950277/
Abstract
摘要